



APASL Oncology 2023 Sendai Oral Free Paper Program

Session #	Date	Time	Room	Category	Submission No.	First Name	Last Name	Country	Title of Abstract
Workshop 1	Oct. 27 (Fri)	9:10-10:10	Room 1 (Sendai A) 4F	Systemic Chemotherapy & Oncology 1	10072	Haruhiko	Takeda	Japan	Multimodal Treatment Strategy with Atezolizumab plus Bevacizumab towards the Complete Response in Unresectable Hepatocellular Carcinoma
					10119	Masashi	Ninomiya	Japan	Late Line Treatment with Atezolizumab plus Bevacizumab Therapy is Less Effective in Unresectable Hepatocellular Carcinoma
					10046	Pil Soo	Sung	Korea	Comparative Analysis of Atezolizumab plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multi-center, Propensity Score Study
					10105	Goki	Suda	Japan	Changes in Serum Growth Factors During Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
					10140	Yutaka	Yasui	Japan	Predictive Factors for Durable Response in Patients Received Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma
Workshop 2	Oct. 27 (Fri)	10:20-11:20	Room 1 (Sendai A) 4F	Systemic Chemotherapy & Oncology 2	10128	Kazufumi	Kobayashi	Japan	A Prospective Study to Assess the Safety and Efficacy of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma Aiming to Maximise Its Potential in Current Clinical Practice
					10137	Naoki	Uchihara	Japan	Prognostic Factors for Survival in Patients with Intermediate-stage Unresectable Hepatocellular Carcinoma Treated with Lenvatinib or Atezolizumab plus Bevacizumab
					10012	Takahiro	Kodama	Japan	Immunokinetic Analysis Predicts Efficacy of Combination Immunotherapy for Advanced Hepatocellular Carcinoma
					10083	Teiji	Kuzuya	Japan	Cabozantinib Therapy in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma-Importance of Good Liver Function and Good Performance Status
					10127	Takahiro	Nishio	Japan	Therapeutic Strategy for Advanced Hepatocellular Carcinoma with Combination of Systemic Therapy and Surgical Resection
Workshop 3	Oct. 27 (Fri)	15:40-16:40	Room 1 (Sendai A) 4F	Liver Cirrhosis (Fibrosis) & Its Complications, NASH/NAFLD	10135	Eiji	Kakazu	Japan	The Difference of Branched-chain Amino Acids Tyrosine Ratio (BTR) among Chronic Liver Disease Comparing to Healthy Adult
					10042	Kouchi	Miura	Japan	Agile 3+ and Agile 4, Non-invasive Tests for Liver Fibrosis, are Excellent Formulae to Predict Liver-related Events in Nonalcoholic Fatty Liver Disease
					10010	Koya	Yasukawa	Japan	Impact of Liver Fibrosis Severity on Oncological Prognosis in Hepatocellular Carcinoma: 1-to-1 Individual Case-matched Analysis
					10016	Harshita	Dubey	India	Impact of Chemotherapy on Liver
					10145	Hltoshi	Mochizuki	Japan	Big Data Analysis of Fatty Liver, Liver Stiffness and Liver Cancer Frequency within Cancer Center Hospitals
Workshop 4	Oct. 27 (Fri)	9:10-10:10	Room 2 (Sendai B) 4F	Basic Science & Pathology 1	10118	Sachiyo	Yoshio	Japan	Immunoglobulin-like Transcript 2 as an Impaired Anti-tumor Cytotoxicity Marker of Natural Killer Cells in Patients with Hepatocellular Carcinoma
					10093	Jun	Arai	Japan	Novel Monoclonal Antibody and ADAM17 Enzymatic Inhibitor could Induce NK Cell-mediated Cytotoxicity in HCC by Targeting NKG2D Ligands
					10100	Hiroyuki	Suzuki	Japan	Fibroblast Growth Factor Inhibition by Molecular-targeted Agents Mitigates Immuno-suppressive Tissue Microenvironment in Hepatocellular Carcinoma
					10099	Kazuyoshi	Kon	Japan	Prevention of Liver Carcinogenesis by Glycine in Hepatocyte-specific PTEN Knockout Mice
					10114	Yuhong	Ma	Japan	Role of ZHX Family Proteins in Hepatocarcinogenesis Studied by Immunohistochemical Staining
Workshop 5	Oct. 27 (Fri)	10:20-11:20	Room 2 (Sendai B) 4F	Basic Science & Pathology 2	10045	Pil Soo	Sung	Korea	Intrahepatic IgA Complex Induces Polarization of Cancer Associated Fibroblasts into the Matrix Phenotype in the Tumor Microenvironment of HCC
					10026	Guang-Zhi	Jin	China	The role and Mechanism of LincRNA Encoded Peptide in the Progression of Hepatocellular Carcinoma
					10067	Ha T.	Nguyen	Japan	Interaction between HSC and LSEC Populations in the Premalignant Environment of DEN-treated Cytoglobin Knock-out Mice
					10041	Charupong	Saengboonmee	Thailand	Anti-proliferative Effects of a Flavonoid from <i>Anomianthus dulcis</i> Sincl. on Hepatocellular Carcinoma
					10096	Naoki	Hashimoto	Japan	Protective Effect of Ischemic Preconditioning on Hepatic Ischemia-reperfusion Injury in Rats
Workshop 6	Oct. 27 (Fri)	15:40-16:40	Room 2 (Sendai B) 4F	Basic Science & Pathology 3	10068	Masao	Nakajima	Japan	Enhancing Tumor Immunogenicity of Hepatocellular Carcinoma using a Novel Cancer Vaccine
					10038	Shinji	Mizuochi	Japan	High-grade Nuclear Atypia is an Unfavorable Factor for Postoperative Recurrence of Hepatocellular Carcinoma
					10017	Amar	Ranjan	India	Findings of Liver Pathology in Autopsy
					10029	Naoki	Hashimoto	Japan	Significance of Partial Portal Arterialization in Small Bowel Transplantation for the Liver
Workshop 7	Oct. 28 (Sat)	9:10-10:10	Room 1 (Sendai A) 4F	Systemic Chemotherapy & Oncology 3	10129	Kazufumi	Kobayashi	Japan	A Prospective Study to Assess the Safety and Efficacy of Ramucirumab in Advanced Hepatocellular Carcinoma Patients in Japanese Real-world Practice: R-evolution Study
					10104	Keisuke	Koroki	Japan	A Randomized Phase II Trial to Assess Safety and Efficacy of Regorafenib in Patients with Advanced Hepatocellular Carcinoma who were not Included in the RESORCE Trial: REGAIN Trial
					10056	Shigeo	Shimose	Japan	Efficacy of Lenvatinib Combined with Transcatheter Intraarterial Therapies for Patients with Advanced-stage of Hepatocellular Carcinoma: A Propensity Score Matching
					10134	Takayoshi	Oikawa	Japan	The Effectiveness of Durvalumab plus Tremelimumab Treatment for Hepatocellular Carcinoma after Treatment with Anti-VEGF Drugs
					10132	Kaoru	Tsuchiya	Japan	Early Experience of Durvalumab plus Tremelimumab in Patients with Unresectable Hepatocellular Carcinoma
Workshop 8	Oct. 28 (Sat)	10:20-11:20	Room 1 (Sendai A) 4F	Systemic Chemotherapy & Oncology 4	10015	Ryo	Yano	Japan	Survival Improvements in Advanced Hepatocellular Carcinoma with Systemic Therapy Over the Past Decade
					10003	Ching-Sheng	Hsu	Taiwan	Association between Presarcopenia and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Systemic Therapy: A Comprehensive Study and Meta-Analysis
					10006	Pil Soo	Sung	Korea	Consistent Efficacy of Hepatic Artery Infusion Chemotherapy Irrespective of PD-L1 Positivity in Unresectable Hepatocellular Carcinoma
					10032	Yuji	Iimuro	Japan	Genetic Discrimination between MC and IM could be Useful in Planning Tumor-specific Treatment Strategies for Recurrent Hepatocellular Carcinoma
					10117	Takanori	Ito	Japan	Abdominal Pain Accompanied by Elevated Serum Inflammatory Markers and Biliary Enzymes for Diagnosing Immune Checkpoint Inhibitor-induced Sclerosing Cholangitis
Workshop 9	Oct. 28 (Sat)	14:35-15:35	Room 1 (Sendai A) 4F	Hepatitis C, Hepatitis B	10115	Jun	Inoue	Japan	Usefulness of FIB-4 Index and ALT at 1 Year of Nucleos(t)ide Analog Treatment for Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients
					10108	Masazumi	Onuki	Japan	MxB Induced in Mitochondria by IFN Inhibits HBV Replication by Activating the RIG-I Signaling Pathway
					10031	Masaaki	Mino	Japan	HCV Clearance Improves Amino Acids Imbalance in Patients with Hepatitis C Regardless of the Presence of Advanced Fibrosis or Previous Treatment of HCC
					10033	Tomoko	Tanaka	Japan	Clinical and Imaging Features of Hypervascular De Novo Hepatocellular Carcinoma after HCV Eradication
					10109	Rie	Goka	Japan	Recurrence and Prognosis of Patients with Primary Hepatocellular Carcinoma Treated with Radiofrequency Ablation
Workshop 10	Oct. 28 (Sat)	15:45-16:45	Room 1 (Sendai A) 4F	Radiotherapy, Imaging & Diagnosis, irAE	10111	Tomokazu	Kawaoka	Japan	Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
					10120	Tamami	Abe	Japan	Establishment of Hepatic Tumor Differentiation and Hepatocellular Carcinoma Grading Method by Quantitative Analysis of Contrast-enhanced Ultrasound Images Using Microbubbles
					10062	Ryo	Izai	Japan	Differentiation of AST/ALT Elevation during Immunotherapy in Patients with Advanced Hepatocellular Carcinoma and Other Cancers
					10121	Mio	Tsuruoka	Japan	The Current Status of IMH in Our Hospital and Experience with the Use of Tacrolimus in Cases Resistant to PSL and MMF
					10147	Shuichiro	Shiina	Japan	Current Status of Tumor Ablation in Japan and Establishment of the Japan Academy of Tumor Ablation (JATA)
Workshop 11	Oct. 28 (Sat)	9:10-10:10	Room 2 (Sendai B) 4F	Surgery & Transplantation	10022	Citra	Aryanti	Indonesia	Choosing Alternative Conduit in Unusable Recipient's Hepatic Artery For Liver Transplantation: A Risk Benefit Analysis Based on Systematic Review and Bayesian Network-Meta Analysis
					10059	Akinobu	Takaki	Japan	Difficulty in Survival Prediction for Hepatocellular Carcinoma and Cholangiocarcinoma after Orthotopic Liver Transplantation
					10116	Takashi	Ito	Japan	Strategy of Living Donor Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
					10149	Kazuaki	Tokodai	Japan	Strategy for Liver Transplantation with Marginal Donor for HCC Cases
					10110	Yukio	Tokumitsu	Japan	Laparoscopic Left Medial Sectionectomy According to Tumor Localization
Workshop 12	Oct. 28 (Sat)	10:20-11:20	Room 2 (Sendai B) 4F	Surgery & Transplantation, TACE, HAIC & Vascular Interventions	10063	Yusuke	Nishi	Japan	The Impact of Local Ablation in Resected Hepatocellular Carcinoma
					10130	Norifumi	Iseda	Japan	Laparoscopic Versus Open Hepatectomy for Hepatocellular Carcinoma
					10097	Naoki	Hashimoto	Japan	Hyperamylasemia after Hepatic Resection
					10064	Hideki	Iwamoto	Japan	The Effectiveness of the Locoregional Treatment Using Hepatic Arterial Infusion Chemotherapy New FP for Locally Progressed Hepatocellular Carcinoma
					10028	Naoki	Hashimoto	Japan	Effect of Distal Splenorenal Shunt plus Splenopancreatic Disconnection on Glucose and Amino Acid Metabolism
Workshop 13	Oct. 28 (Sat)	14:35-15:35	Room 2 (Sendai B) 4F	Tumor Markers & Biochemistry, CCC, Others	10051	Munkhbayar	Semchin	Mongolia	Diagnostic Value of Serum GPC3 in Early Stage of HCC
					10086	Hongping	Xia	Singapore	Metabolic Profiling Identifies Key Metabolic Biochemical Pathways Associated with Recurrence of Hepatocellular Carcinoma
					10112	Alzhrara	Alkhatib	Egypt	The Bile Level of Cytokeratin 7 as a Diagnostic Marker for Cholangiocarcinoma
					10023	Edwin N	Njoto	Indonesia	The Effects of Hepatic Arterial Infusion on Survival in Patients with Intrahepatic Cholangiocarcinoma: A Meta-Analysis
					10141	Hiroto	Ota	Japan	Efficacy of NewFP Therapy for Unresectable Advanced Intrahepatic Cholangiocarcinoma
10136	Kenji	Amemiya	Japan	Support and Implementation system for Clinical Cancer Research at the Prefectural Designated Regional Cancer Centers and Hospital					

Presentation Time:
9 min. Presentation
3 min. Discussion
12 min. Total each